Global Endometriosis Expert Headlines Launch of Groundbreaking New Treatment for Women in Malta

A recent wave of national awareness and deeply personal stories in the media made the conversation around endometriosis in Malta louder and more urgent. Now, in a breakthrough development, local wellness and pharmaceutical leader Vivian has launched a new oral treatment for women suffering from this chronic and often misunderstood condition.

The launch of this new treatment was addressed by internationally acclaimed endometriosis specialist, Prof. Jacques Donnez, a renowned Belgian gynaecologist and, recently, the recipient of the Endometriosis Foundation of America’s prestigious Harry Reich Award.

Prof. Donnez, who has focused much of his research for the past 40 years on endometriosis, tubal infertility, and ovarian cryopreservation and transplantation, is globally recognised for his pioneering work in minimally invasive gynaecologic surgery and his commitment to advancing endometriosis care.

Endometriosis affects approximately 1 in 10 women of reproductive age, yet access to effective treatment in Malta has remained limited.

Characterised by the growth of tissue similar to the uterine lining outside the womb, endometriosis is associated with chronic pelvic pain, heavy menstrual bleeding, fatigue, and infertility.

Many women have faced years of misdiagnoses and were left with little more than dietary recommendations, painkillers, or hormonal therapies that may not have worked for everyone. Vivian’s introduction of this new treatment marks a significant shift, from simply raising awareness to delivering a clinically proven, targeted treatment.

“Until now, the conversation around endometriosis in Malta has centred on lifestyle changes and symptom management,” says Daniela Magro from Vivian’s Women’s Health Unit. “With this new treatment, we are finally able to offer patients an effective, non-invasive solution that addresses the root hormonal mechanisms of the disease, giving women not just hope, but real relief.”

The daily oral treatment leads primarily to reduced oestrogen levels to relieve endometriosis-associated pain. At certain doses, hormone levels are maintained high enough to minimise the need for add-back therapy. This dose-dependent suppression allows a tailored approach that balances efficacy with long-term safety considerations.

The treatment is already approved in several countries across Europe, and two months ago, it was also approved for use on the UK’s NHS where it is already being seen as a game-changer in the management of endometriosis and uterine fibroids.

Vivian has long been at the forefront of bringing innovative medical solutions to Malta, and the launch of this treatment was accompanied by an informative session for gynaecologists.

“This launch goes beyond the treatment,” added Daniela. “It’s about empowering women with choices, bridging years of neglect, and moving decisively from awareness to action.”

Available by prescription and administered under specialist guidance, the new treatment represents a significant advancement over existing therapies by reducing reliance on invasive procedures and providing a convenient oral option with well-documented clinical results.